Prospective study demonstrates EndoPredict® can guide chemotherapy decision for women
Myriad Genetics announced that researchers from the Technical University of Munich reported the first prospective outcomes data on EndoPredict®. One of the key findings is that EndoPredict high-risk patients had a better outcome with adjuvant chemotherapy compared to endocrine therapy alone. December 07, 2018